Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing ...
As of Friday, January 23, Molecular Partners AG’s MOLN share price has surged by 6.99%, which has investors questioning if ...
Shares of Molecular Partners AG Sponsored ADR (MOLN) have been struggling lately and have lost 11.3% over the past week. However, a hammer chart pattern was formed in its last trading session, which ...
Fintel on MSN
HC Wainwright & Co. initiates coverage of Molecular Partners AG - Depositary Receipt (MOLN) with buy recommendation
Fintel reports that on January 27, 2026, HC Wainwright & Co. initiated coverage of Molecular Partners AG - Depositary Receipt ...
Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Spare a thought for those who held Molecular Partners AG (VTX:MOLN) for five whole years - as the share ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
Molecular Partners develops DARPin proteins for oncology and virology, offering advantages over traditional antibodies. The company's Switch-DARPin platform offers conditional and reversible immune ...
MOLN is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of MOLN shares has increased $0.06 since the market last closed. This is a 1.47% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results